binx health, inc. announced a national distribution agreement with Cardinal Health to expand access to care with the CLIA-waived, FDA-cleared binx io® to improve the timely diagnosis of chlamydia (CT) and gonorrhea (NG). The binx io changes the testing and treatment paradigm, by delivering central lab equivalent results within the time window of a typical clinic visit. Collaborating with Cardinal Health provides binx health with additional access to the acute clinical care settings via its vast sales network in the market.

This improved access will provide patients the ability to benefit from the binx io CT/NG Assay in clinics, primary care offices, Emergency Departments, and hospital-affiliated urgent cares in a single patient visit nationwide. The binx io is the only CLIA-waived, FDA-cleared molecular point-of-care (POC) platform to detect CT and NG in both male and female patient samples that provides central lab performance in about thirty minutes. Data presented at the STI & HIV 2023 World Congress in Chicago demonstrated that hands-on-time for the POC binx io is statistically the same as the hands-on-time for processing a CT/NG sample for send out to a central lab.

CT/NG results from the binx io were available days before test results were available from the central lab CT/NG test. With this distribution collaboration, together binx health and Cardinal Health teams will help improve access to the treatment of CT/NG.